PMLiVE11h
Merck’s adult-specific pneumococcal vaccine Capvaxive recommended by CHMP
The Committee for Medicinal Products for Human Use (CHMP) has recommended that Capvaxive be used to prevent invasive disease ...
emjreviews.com15h
LS-SCLC Immunotherapy Treatment Recommended for Approval
Immunotherapy has shown a 27% reduction in mortality for patients with limited-stage small cell lung cancer, based on Phase ...
Merck & Co., Inc. (NYSE:MRK) Q4 2024 Earnings Call Transcript
Q4 2024 Earnings Call Transcript February 4, 2025 Merck & Co., Inc. misses on earnings expectations. Reported EPS is $1.72 ...
Merck stock price target lowered to $129 by Goldman Sachs
Goldman Sachs analyst Chris Shibutani adjusted the price target for Merck (NSE:PROR) & Co. Inc. (NYSE:MRK) to $129.00, down from the previous $135.00, while reiterating a Buy rating on the ...
manilatimes9h
Serplulimab Approved in the EU for First-Line Treatment of Extensive-Stage Small Cell Lung Cancer (ES-SCLC)
Serplulimab is the world's first anti-PD-1 monoclonal antibody (mAb) approved for first-line treatment of ES-SCLC Serplulimab is the first and only anti-PD-1 mAb approved in the European Union (EU) ...